Article

Thomas Maddox, MD: Impact of COVID-19 on the American College of Cardiology

Discussing how the ACC has responded to the ongoing outbreak and the potential lasting impact of COVID-19 on the College.

At this point in the outbreak, the impact of coronavirus disease 2019 (COVID-19) on major medical organizations is obvious.

Despite rocking the medical community, these same organizations have led the charge in educating and aiding clinicians in the wake of the outbreak. From releasing new guidance to providing insights and perspectives on new data, nearly every organization has been impacted by the ongoing pandemic, including the American College of Cardiology (ACC).

In an effort to provide the latest and most accurate information to its members and other cardiologists or clinicians throughout the world, the College created the “COVID-19 Hub” on their website. Containing clinical guidance, front line perspectives, highlighted journal articles, and more, the ACC’s Science and Quality Committee created the Hub as a comprehensive aggregate highlighting key information surrounding the ongoing outbreak.

In addition to creating a central landing page for clinicians seeking data related to COVID-19, the organization was also forced to take its annual meeting virtual. Originally scheduled to be held in Chicago, the ACC managed to publish thousands of abstracts, including video presentations of late-breaking data, in a format that was free for participants.

For a better understanding on how the ongoing outbreak has impacted the ACC, HCPLive® sat down with Thomas Maddox, MD, professor of medicine at Washington University School of Medicine and chair of the American College of Cardiology.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.